Previous studies 12, 13 have shown that IgG, C3 and C4 can be used as indicators to monitor the active stage of SLE disease, and hematologic involvement in the clinical diagnostic guidelines of SLE disease was also classified as the performance of SLE disease activity. This evidence concerns the gene C4A and systemic lupus erythematosus.